


**eNOS (phospho Ser615) Polyclonal Antibody**


<b>Catalog No :</b>	YP0381
<b>Reactivity :</b>	Human;Mouse;Rat
<b>Applications :</b>	WB;ELISA
<b>Target :</b>	NOS3
<b>Fields :</b>	>>Arginine biosynthesis;>>Arginine and proline metabolism;>>Metabolic pathways;>>Calcium signaling pathway;>>cGMP-PKG signaling pathway;>>HIF-1 signaling pathway;>>Sphingolipid signaling pathway;>>PI3K-Akt signaling pathway;>>VEGF signaling pathway;>>Apelin signaling pathway;>>Platelet activation;>>Estrogen signaling pathway;>>Oxytocin signaling pathway;>>Relaxin signaling pathway;>>Insulin resistance;>>AGE-RAGE signaling pathway in diabetic complications;>>Diabetic cardiomyopathy;>>Lipid and atherosclerosis;>>Fluid shear stress and atherosclerosis
<b>Gene Name :</b>	NOS3
<b>Protein Name :</b>	Nitric oxide synthase endothelial
<b>Human Gene Id :</b>	4846
<b>Human Swiss Prot No :</b>	P29474
<b>Mouse Gene Id :</b>	18127
<b>Mouse Swiss Prot No :</b>	P70313
<b>Rat Gene Id :</b>	24600
<b>Rat Swiss Prot No :</b>	Q62600
<b>Immunogen :</b>	The antiserum was produced against synthesized peptide derived from human eNOS around the phosphorylation site of Ser615. AA range:581-630
<b>Specificity :</b>	Phospho-NOS3 (S615) Polyclonal Antibody detects endogenous levels of NOS3 protein only when phosphorylated at S615.

<b>Formulation :</b>	<u>Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.</u>
<b>Source :</b>	<u>Polyclonal, Rabbit,IgG</u>
<b>Dilution :</b>	<u>WB 1:500 - 1:2000. ELISA: 1:40000. Not yet tested in other applications.</u>
<b>Purification :</b>	<u>The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.</u>
<b>Concentration :</b>	<u>1 mg/ml</u>
<b>Storage Stability :</b>	<u>-15°C to -25°C/1 year(Do not lower than -25°C)</u>
<b>Observed Band :</b>	<u>130-140kD</u>
<b>Cell Pathway :</b>	<u>Regulates Angiogenesis; AMPK; Akt_PKB; Protein_Acetylation</u>
<b>Background :</b>	<u>Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009],</u>
<b>Function :</b>	<u>catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+).,cofactor:binds 1 FAD.,cofactor:binds 1 FMN.,cofactor:heme group.,cofactor:tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.,enzyme regulation:stimulated by calcium/calmodulin. inhibited by NOSIP and NOSTRIN.,function:produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.,online information:nitric oxide synthase entry,polymorphism:variation in NOS3 seem to be associated with susceptibility to coronary spasm.,similarity:belongs to the NOS family.,similarity:contains 1 FAD-binding FR-type domain.,similarity:contains 1 flavodoxin-like</u>
<b>Subcellular Location :</b>	<u>Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity.</u>
<b>Expression :</b>	<u>Platelets, placenta, liver and kidney.</u>

## Products Images



Enzyme-Linked Immunosorbent Assay (Phospho-ELISA) for Immunogen Phosphopeptide (Phospho-left) and Non-Phosphopeptide (Phospho-right), using eNOS (Phospho-Ser615) Antibody



Western blot analysis of lysates from K562 cells treated with EGF 40nM 30', using eNOS (Phospho-Ser615) Antibody. The lane on the right is blocked with the phospho peptide.